Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with oestrogen-receptor-positive (ER+), HER2-negative breast cancer. Here, we descr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:NPJ Breast Cancer
Glavni autori: Buus, Richard, Szijgyarto, Zsolt, Schuster, Eugene F., Xiao, Hui, Haynes, Ben P., Sestak, Ivana, Cuzick, Jack, Paré, Laia, Seguí, Elia, Chic, Nuria, Prat, Aleix, Dowsett, Mitch, Cheang, Maggie Chon U.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7881187/
https://ncbi.nlm.nih.gov/pubmed/33579961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00216-w
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items